CARTaGENE Project

Lead Contact and/or Principal Investigator (PI):

  • Philip Awadalla, Ph.D.
    CHU Ste.-Justine (CARTaGENE), University of Montreal

Funded Since: 2009
Funding Source: Genome Québec, Canadian Partnership for Tomorrow Project (CPTP)
Year(s) of Enrollment: 2009
Study Website: http://www.cartagene.qc.caExternal Web Site Policy

Launched in October 2009, the CARTaGENE project is the largest prospective longitudinal cohort of Québec. CARTaGENE's distinguishing features are that it is a quantitative prospective cohort that has deeply phenotyped 20,000 individuals aged 40-69, the age most individuals will develop chronic disease. 37,000 individuals will be enrolled by 2014. It is an open-access infrastructure enabling researchers to investigate the genetic, environmental, and lifestyle determinants of disease in the French Canadian population. CARTaGENE has collected whole blood for DNA from 30,000 individuals. The DNA will soon be available for access (20,000). It is one of the only cohorts worldwide to collect blood for RNA (9,000), thereby enabling gene expression studies, and to collect full residential and occupational history along with detailed nutrition information on its participants. In addition to current recruitment efforts, CARTaGENE's focus is to recontact the baseline cohort with follow-up questionnaires, whole genome genotyping of 30,000 individuals, and continued enrichment of the resource through linkage to administrative health records (RAMQ) and returned data from past projects. The CARTaGENE project is a strategic project of the CHU Ste.-Justine Children's Hospital and the Canadian Partnership Against Cancer.

Return to Top